ProQR Therapeutics CEO Buys $238.5K in Open Market Shares
PRQR sits 21% above its 52-week low of $1.33.
Summary
ProQR Therapeutics CEO Daniel Anton de Boer purchased $238,500 worth of company shares in the open market, indicating executive confidence.
Key Events · Ownership and Investor Activity · PRQR
-
CEO Open Market Purchase
Daniel Anton de Boer, CEO and Director, acquired 150,000 ordinary shares for a total of $238,500 in an open market transaction on July 7, 2026.
-
Executive Conviction
This open market purchase (Code P) represents a direct investment by the CEO, signaling personal conviction in the company's value and future outlook.
-
Post-Capital Raise Confidence
The purchase follows a recent successful capital raise of nearly $60 million and positive Phase 1 clinical data for AX-0810, suggesting the CEO sees value after these events.
Analysis · PRQR · Life Sciences
The CEO's open market purchase of nearly $240,000 in company stock signals strong confidence following recent positive Phase 1 clinical data and a successful capital raise. This direct investment by a key executive suggests a belief in the company's future prospects, especially after a period that included a significant capital increase and a shareholder dispute.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRQR was trading at $1.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $214.8M. The 52-week trading range was $1.33 to $3.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.